Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 13/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 7/20 | 0.42 |
| ▸ | TP53 | P04637 | 5/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622707 | 1.00 | FAAH (0.43) | FAAHDAGLATP53SHMT2POLB | |
| SCHEMBL5466852 | 0.84 | RAB9A (0.40) | FAAHTP53MAPTCES1 | |
| SCHEMBL5513719 | 0.84 | RAB9A (0.40) | FAAHTP53MAPTCES1 | |
| SCHEMBL7261195 | 0.78 | FAAH (0.43) | FAAHDAGLATP53 | |
| SCHEMBL3620329 | 0.77 | FAAH (0.39) | FAAHDAGLATP53POLBMAPT | |
| SCHEMBL5415877 | 0.75 | — | — | |
| SCHEMBL5461922 | 0.74 | ALDH1A1 (0.42) | FAAHPOLBMAPTCES1 | |
| SCHEMBL5420085 | 0.74 | ALDH1A1 (0.42) | FAAHPOLBMAPTCES1 | |
| SCHEMBL5945966 | 0.74 | ALDH1A1 (0.42) | FAAHPOLBMAPTCES1 | |
| SCHEMBL5489548 | 0.73 | FAAH (0.44) | FAAHDAGLATP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | disclosed |
| US-7101880-B2 | Peptidic compounds as cysteine protease inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | FAAH 856/4885DAGLA 2816/4885TP53 657/4885 |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | CTSV, CTSB, CTSS | FAAH 1228/4885DAGLA 3515/4885TP53 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.